Literature DB >> 19865501

Clinical strategies for supporting the untransfusable hemorrhaging patient.

Gavin M Melmed1, Meredith E Hulsey, Mike Newhouse, Houston E Holmes, Edward J Mays.   

Abstract

Hemorrhaging patients who cannot be transfused due to personal beliefs or the lack of compatible blood products provide a unique challenge for clinicians. Here we describe a 58-year-old African American man with a history of sickle cell-beta(+) thalassemia who had recently received a multiunit exchange transfusion and developed hematochezia followed by severe anemia. Due to the presence of multiple alloantibodies, no compatible packed red blood cell (pRBC) units could initially be located. The patient was managed with mechanical ventilation, colloid and crystalloid solutions, procoagulants, and recombinant erythropoietin. After an extensive search by our blood bank, enough compatible pRBC units were identified and the patient survived without significant clinical sequelae. Management of the untransfusable hemorrhaging patient requires a multidisciplined approach, with coordination between blood banks, hematologists, intensivists, and other specialists. Steps should be taken to avoid or limit blood loss, identify compatible pRBC units, control hypotension, maximize oxygen delivery, minimize metabolic demand, and stimulate erythropoiesis. In dire circumstances, use of experimental hemoglobin substitutes or transfusion of the least serologically incompatible pRBCs available may be considered.

Entities:  

Year:  2009        PMID: 19865501      PMCID: PMC2760162          DOI: 10.1080/08998280.2009.11928545

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  41 in total

1.  Blood substitute and erythropoietin therapy in a severely injured Jehovah's witness.

Authors:  Clay Cothren; Ernest E Moore; Patrick J Offner; James B Haenel; Jeffrey L Johnson
Journal:  N Engl J Med       Date:  2002-04-04       Impact factor: 91.245

2.  Hyperhemolytic transfusion reaction in sickle cell disease.

Authors:  N Win; H Doughty; P Telfer; B J Wild; T C Pearson
Journal:  Transfusion       Date:  2001-03       Impact factor: 3.157

3.  Aortic dissection and hypothermic arrest in a Jehovah's Witness patient: a case for recombinant factor VIIa?

Authors:  Jenifer Ballen; Michael Raabe; Brian Muirhead
Journal:  Can J Anaesth       Date:  2006-04       Impact factor: 5.063

4.  Blood group antibodies and their significance in transfusion medicine.

Authors:  Joyce Poole; Geoff Daniels
Journal:  Transfus Med Rev       Date:  2007-01

5.  Correction of excessive anticoagulation with low-dose oral vitamin K1.

Authors:  R T Weibert; D T Le; S R Kayser; S I Rapaport
Journal:  Ann Intern Med       Date:  1997-06-15       Impact factor: 25.391

6.  RBC antibody persistence.

Authors:  H Schonewille; H L Haak; A M van Zijl
Journal:  Transfusion       Date:  2000-09       Impact factor: 3.157

7.  Severe anemia after gastrointestinal hemorrhage in a Jehovah's Witness: new treatment strategies.

Authors:  Christopher J Gannon; Lena M Napolitano
Journal:  Crit Care Med       Date:  2002-08       Impact factor: 7.598

8.  Mild hypothermia alters the oxygen consumption/delivery relationship by decreasing the slope of the supply-dependent line.

Authors:  Jun Oda; Yasuyuki Kuwagata; Yasushi Nakamori; Mitsuhiro Noborio; Toshiaki Hayakata; Satoshi Fujimi; Hisashi Sugimoto
Journal:  Crit Care Med       Date:  2002-07       Impact factor: 7.598

9.  Compared with crystalloid, colloid therapy slows progression of extrapulmonary tissue injury in septic sheep.

Authors:  H Morisaki; F Bloos; J Keys; C Martin; A Neal; W J Sibbald
Journal:  J Appl Physiol (1985)       Date:  1994-09

10.  [Treatment of post-traumatic acute anemia by recombinant human erythropoietin in Jehovah's Witnesses].

Authors:  C Streef; C Charpentier; G Audibert; M C Laxenaire
Journal:  Ann Fr Anesth Reanim       Date:  1996
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.